Release date: 5 December 2014
Promoter – Financial Intermediary
MERCK KGaALocation
Description
Research and development (R&D) investments in clinical development in the oncology and immunology fields between 2015 and 2018.
Objectives
The project covers Merck's research activities in oncology and immunology.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 400 million
Total cost (Approximate amount)
EUR 888 million
Environmental aspects
The project concerns investments in research and development that will be carried out in existing facilities without changing their already authorised scope. An environmental impact assessment (EIA) is therefore not required by EIA Directive 2011/92/EU. The promoter has an integrated environmental management policy and effective operating procedures in place which are in line with best industry standards.
Procurement
The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU directives on procurement. However, the promoter’s procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank’s services will verify details during the project due diligence.
Status
Signed - 29/05/2015
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).